GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Sagent Pharmaceuticals Inc (NAS:SGNT) » Definitions » Price-to-Owner-Earnings

Sagent Pharmaceuticals (Sagent Pharmaceuticals) Price-to-Owner-Earnings : (As of May. 05, 2024)


View and export this data going back to 2011. Start your Free Trial

What is Sagent Pharmaceuticals Price-to-Owner-Earnings?

As of today (2024-05-05), Sagent Pharmaceuticals's share price is $21.76. Sagent Pharmaceuticals does not have enough data to calculate Owner Earnings per Share (TTM), so as pPrice-to-Owner-Earnings.


The historical rank and industry rank for Sagent Pharmaceuticals's Price-to-Owner-Earnings or its related term are showing as below:


SGNT's Price-to-Owner-Earnings is not ranked *
in the Drug Manufacturers industry.
Industry Median: 28.05
* Ranked among companies with meaningful Price-to-Owner-Earnings only.

As of today (2024-05-05), Sagent Pharmaceuticals's share price is $21.76. Sagent Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2016 was $-0.77. Therefore, Sagent Pharmaceuticals's PE Ratio for today is At Loss.

As of today (2024-05-05), Sagent Pharmaceuticals's share price is $21.76. Sagent Pharmaceuticals's EPS without NRI for the trailing twelve months (TTM) ended in was $-0.77. Therefore, Sagent Pharmaceuticals's PE Ratio without NRI for today is At Loss.


Sagent Pharmaceuticals Price-to-Owner-Earnings Historical Data

The historical data trend for Sagent Pharmaceuticals's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sagent Pharmaceuticals Price-to-Owner-Earnings Chart

Sagent Pharmaceuticals Annual Data
Trend Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15
Price-to-Owner-Earnings
Get a 7-Day Free Trial - - - 19.39 -

Sagent Pharmaceuticals Quarterly Data
Sep11 Dec11 Mar12 Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16
Price-to-Owner-Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 38.40 60.12 - - -

Competitive Comparison of Sagent Pharmaceuticals's Price-to-Owner-Earnings

For the Drug Manufacturers - Specialty & Generic subindustry, Sagent Pharmaceuticals's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sagent Pharmaceuticals's Price-to-Owner-Earnings Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Sagent Pharmaceuticals's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where Sagent Pharmaceuticals's Price-to-Owner-Earnings falls into.



Sagent Pharmaceuticals Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

Sagent Pharmaceuticals's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings=Share Price/Owner Earnings per Share (TTM)
=21.76/0.00
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Sagent Pharmaceuticals  (NAS:SGNT) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.


Sagent Pharmaceuticals Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of Sagent Pharmaceuticals's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.


Sagent Pharmaceuticals (Sagent Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
Sagent Pharmaceuticals Inc is a Delaware corporation that was incorporated in 2011. The Company was initially founded in 2006 as Sagent Holding Co., a Cayman Islands company, it reincorporated as Sagent Pharmaceuticals, Inc., a Delaware corporation, in connection with its initial public offering, on April 26, 2011. The Company is engaged in the developing, manufacturing, sourcing and marketing injectable pharmaceutical products, which it sells primarily in the United States of America. The Company primarily focuses on generic injectable pharmaceuticals, which provide customers a lower-cost alternative to branded products when applicable patents have expired or been declared invalid, or when the products are determined not to infringe the patents of others, it offers customers, products across anti-infective, oncolytic and critical care indications in a variety of presentations, including single- and multi-dose vials and ready-to-use pre-filled syringes and premix bags. It generally seeks to develop injectable products where the form or packaging of the product can be enhanced to improve delivery, product safety or end-user convenience. At the year end, the Company's product portfolio has grown to a total of 53 products which can be classified into the following three product categories: anti-infective, oncology and critical care. Its anti-infective products assist in the treatment of various infections and related symptoms, its oncology products are used in the treatment of cancer and cancer-related medical problems, and its critical care products are used in a variety of critical care applications and include anesthetics, cardiac medications, steroidal products and sedatives. The Company distributes its products primarily through pharmaceutical wholesalers and, to a lesser extent, specialty distributors that focus on particular therapeutic product categories, for use by a wide variety of end-users, including U.S. hospitals, integrated delivery networks and alternative site facilities. The Company's principal competitors include Fresenius Kabi, a division of Fresenius SE, Hospira, Inc., Pfizer Inc., Sandoz International GmbH, a division of Novartis AG, Teva Pharmaceutical Industries Ltd. and West-Ward Pharmaceutical Corp. The Company is subject to extensive regulation by governmental authorities in the U.S. and in other countries.
Executives
Shlomo Yanai director ONE MEADOWLANDS PLAZA, EAST RUTHERFORD NJ 07073
Vivo Ventures V, Llc 10 percent owner 505 HAMILTON AVENUE, SUITE 200, PALO ALTO CA 94301
Vivo Ventures V Affiliates Fund, L.p. 10 percent owner 575 HIGH STREET, SUITE 201, PALO ALTO CA 94301
Vivo Ventures Fund V, L.p. 10 percent owner 505 HAMILTON AVENUE, SUITE 200, PALO ALTO CA 94301
Jonathon M Singer officer: EVP and CFO 520 LAKE COOK ROAD, SUITE 315, DEERFIELD IL 60015
Michael Fekete director C/O SAGENT PHARMACEUTICALS, INC., 1901 NORTH ROSELLE ROAD, SUITE 700, SCHAUMBURG IL 60195
Robert J Flanagan director C/O SAGENT PHARMACEUTICALS, INC., 1901 NORTH ROSELLE ROAD, SUITE 700, SCHAUMBURG IL 60195
Sean Brynjelsen officer: EVP, Business Development C/O ETON PHARMACEUTICALS, INC., 21925 W FIELD PKWY #235, DEER PARK IL 60010
Vivo Ventures Vi Affiilates Fund, L.p. 10 percent owner 575 HIGH STREET, SUITE 201, PALP ALTO CALIFORNIA CA 94301
Vivo Ventures Fund Vi, L.p. 10 percent owner 575 HIGH STREET, SUITE 201, PALO ALTO CA 94301
Vivo Ventures Vi, Llc 10 percent owner 505 HAMILTON AVENUE, SUITE 200, PALO ALTO CA 94301
Frank Kung director C/O VIVO CAPITAL, 505, PALO ALTO CA 94301
Jeffrey Yordon director
Morgan Stanley Investment Management Inc 10 percent owner 1221 AVENUE OF AMERICAS, NEW YORK NY 10020
Ronald Pauli officer: Chief Financial Officer 2730 WILSHIRE BLVD., #500, LOS ANGELES CA 90403

Sagent Pharmaceuticals (Sagent Pharmaceuticals) Headlines

No Headlines